Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer
Authors:
- 27 October 2011
- journal article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 12 (7) , 574-585
Abstract
Poor prognosis cancers, such as pancreatic cancer, represent inherent challenges for ceramide-based nanotherapeutics due to metabolic pathways, which neutralize ceramide to less toxic or pro-oncogenic metabolites. We have recently developed a novel 80 nanometer diameter liposomal formulation that incorporates 30 molar percent C6-ceramide, a bioactive lipid that is pro-apoptotic to many cancer cells, but not to normal cells. In this manuscript, we evaluated the efficacy of combining nanoliposomal C6-ceramide (Lip-C6) with either gemcitabine or an inhibitor of glucosylceramide synthase. We first assessed the biological effect of Lip-C6 in PANC-1 cells, a gemcitabine-resistant human pancreatic cancer cell line, and found that low doses alone did not induce cell toxicity. However, cytotoxicity was achieved by combining Lip-C6 with either non-toxic sub-therapeutic concentrations of gemcitabine or with the glucosylceramide synthase inhibitor D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP). Furthermore, these combinations with Lip-C6 cooperatively inhibited PANC-1 tumor growth in vivo. Mechanistically, Lip-C6 inhibited pro-survival Akt and Erk signaling, whereas the nucleoside analog gemcitabine did not. Furthermore, by including PDMP within the nanoliposomes, which halted ceramide neutralization as evidenced by LC-MS3, the cytotoxic effects of Lip-C6 were enhanced. Collectively, we have demonstrated that nanoliposomal ceramide can be an effective anti-pancreatic cancer therapeutic in combination with gemcitabine or an inhibitor of ceramide neutralization.Keywords
This publication has 50 references indexed in Scilit:
- Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectinNature Medicine, 2010
- Inhibition of NADPH oxidase by glucosylceramide confers chemoresistanceCancer Biology & Therapy, 2010
- Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemiaBlood, 2010
- Metabolism of short-chain ceramide by human cancer cells—Implications for therapeutic approachesBiochemical Pharmacology, 2010
- Bioconjugation of Calcium Phosphosilicate Composite Nanoparticles for Selective Targeting of Human Breast and Pancreatic Cancers In VivoACS Nano, 2010
- Downregulation of neutral ceramidase by gemcitabine: Implications for cell cycle regulationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- Atypical Protein Kinase Cι Expression and Aurothiomalate Sensitivity in Human Lung Cancer CellsCancer Research, 2008
- A role for ceramide in driving cancer cell resistance to doxorubicinThe FASEB Journal, 2008
- Roles of Bioactive Sphingolipids in Cancer Biology and Therapeutics2008
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007